Skip to main content Back to Top
Advertisement

3/25/2020

Ketamine Injection

Products Affected - Description

    • Ketamine injection, Pfizer, 100 mg/mL, 5 mL vial, 10 count, NDC 00409-2051-05
    • Ketamine injection, Pfizer, 50 mg/mL, 10 mL vial, 10 count, NDC 00409-2053-10

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has ketamine available.
    • Par has Ketalar available.
    • Pfizer has ketamine on shortage due to manufacturing delays.

Available Products

    • Ketalar injection, Par Pharmaceuticals, 10 mg/mL, 20 mL vial, 10 count, NDC 42023-0113-10
    • Ketalar injection, Par Pharmaceuticals, 100 mg/mL, 5 mL vial, 10 count, NDC 42023-0115-10
    • Ketalar injection, Par Pharmaceuticals, 50 mg/mL, 10 mL vial, 10 count, NDC 42023-0114-10
    • Ketamine injection, Hikma, 100 mg/mL, 5 mL vial, 10 count, NDC 00143-9509-10
    • Ketamine injection, Hikma, 50 mg/mL, 10 mL vial, 10 count, NDC 00143-9508-10
    • Ketamine injection, Mylan Institutional, 10 mg/mL, 20 mL vial, 10 count, NDC 67457-0181-20
    • Ketamine injection, Mylan Institutional, 100 mg/mL, 10 mL vial, 10 count, NDC 67457-0108-10
    • Ketamine injection, Mylan Institutional, 50 mg/mL, 10 mL vial, 10 count, NDC 67457-0001-10

Estimated Resupply Dates

    • Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of January 2021. The 100 mg/mL 5 mL vials are available in limited supply.

Updated

Updated March 25, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.